Literature DB >> 28784776

Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis.

Yi Seok Chang1,2, Swati P Jalgaonkar1,2, Justin D Middleton1,2, Tsonwin Hai3,2.   

Abstract

Chemotherapy is a double-edged sword. It is anticancer because of its cytotoxicity. Paradoxically, by increasing chemoresistance and cancer metastasis, it is also procancer. However, the underlying mechanisms for chemotherapy-induced procancer activities are not well understood. Here we describe the ability of paclitaxel (PTX), a frontline chemotherapeutic agent, to exacerbate metastasis in mouse models of breast cancer. We demonstrate that, despite the apparent benefit of reducing tumor size, PTX increased the circulating tumor cells in the blood and enhanced the metastatic burden at the lung. At the primary tumor, PTX increased the abundance of the tumor microenvironment of metastasis, a landmark microanatomical structure at the microvasculature where cancer cells enter the blood stream. At the metastatic lung, PTX improved the tissue microenvironment (the "soil") for cancer cells (the "seeds") to thrive; these changes include increased inflammatory monocytes and reduced cytotoxicity. Importantly, these changes in the primary tumor and the metastatic lung were all dependent on Atf3, a stress-inducible gene, in the noncancer host cells. Together, our data provide mechanistic insights into the procancer effect of chemotherapy, explaining its paradox in the context of the seed-and-soil theory. Analyses of public datasets suggest that our data may have relevance to human cancers. Thus, ATF3 in the host cells links a chemotherapeutic agent-a stressor-to immune modulation and cancer metastasis. Dampening the effect of ATF3 may improve the efficacy of chemotherapy.

Entities:  

Keywords:  ATF3; chemotherapy; immune modulation; metastasis; stress response

Mesh:

Substances:

Year:  2017        PMID: 28784776      PMCID: PMC5576783          DOI: 10.1073/pnas.1700455114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  75 in total

Review 1.  Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.

Authors:  P Corradini; M Ladetto; A Pileri; C Tarella
Journal:  Leukemia       Date:  1999-11       Impact factor: 11.528

2.  A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion.

Authors:  Manuela Quintavalle; Leonardo Elia; Jeffrey H Price; Susanne Heynen-Genel; Sara A Courtneidge
Journal:  Sci Signal       Date:  2011-07-26       Impact factor: 8.192

3.  Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.

Authors:  Lisa Volk-Draper; Kelly Hall; Caitlin Griggs; Sandeep Rajput; Pascaline Kohio; David DeNardo; Sophia Ran
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

4.  Male breast cancer: a population-based comparison with female breast cancer.

Authors:  William F Anderson; Ismail Jatoi; Julia Tse; Philip S Rosenberg
Journal:  J Clin Oncol       Date:  2009-12-07       Impact factor: 44.544

5.  Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.

Authors:  Masahisa Jinushi; Shigeki Chiba; Hironori Yoshiyama; Kenkichi Masutomi; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Hideo Yagita; Akinori Takaoka; Hideaki Tahara
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

6.  Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice.

Authors:  Svetlana Gingis-Velitski; David Loven; Liat Benayoun; Michal Munster; Rotem Bril; Tali Voloshin; Dror Alishekevitz; Francesco Bertolini; Yuval Shaked
Journal:  Cancer Res       Date:  2011-10-06       Impact factor: 12.701

7.  Comparative proteomic analysis of paclitaxel resistance-related proteins in human breast cancer cell lines.

Authors:  Hiroya Fujioka; Akiko Sakai; Satoru Tanaka; Kosei Kimura; Akiko Miyamoto; Mitsuhiko Iwamoto; Kazuhisa Uchiyama
Journal:  Oncol Lett       Date:  2016-11-30       Impact factor: 2.967

8.  Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.

Authors:  Theodoros Foukakis; John Lövrot; Patricia Sandqvist; Hanjing Xie; Linda S Lindström; Carla Giorgetti; Hans Jacobsson; Elham Hedayati; Jonas Bergh
Journal:  Mol Oncol       Date:  2015-04-03       Impact factor: 6.603

9.  A stromal gene signature associated with inflammatory breast cancer.

Authors:  Brenda J Boersma; Mark Reimers; Ming Yi; Joseph A Ludwig; Brian T Luke; Robert M Stephens; Harry G Yfantis; Dong H Lee; John N Weinstein; Stefan Ambs
Journal:  Int J Cancer       Date:  2008-03-15       Impact factor: 7.396

10.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.

Authors:  Mélanie Bruchard; Grégoire Mignot; Valentin Derangère; Fanny Chalmin; Angélique Chevriaux; Frédérique Végran; Wilfrid Boireau; Benoit Simon; Bernhard Ryffel; Jean Louis Connat; Jean Kanellopoulos; François Martin; Cédric Rébé; Lionel Apetoh; François Ghiringhelli
Journal:  Nat Med       Date:  2012-12-02       Impact factor: 53.440

View more
  54 in total

1.  Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer.

Authors:  Jessica M Pastoriza; George S Karagiannis; Juan Lin; Sonali Lanjewar; David Entenberg; John S Condeelis; Joseph A Sparano; Xiaonan Xue; Thomas E Rohan; Maja H Oktay
Journal:  Clin Exp Metastasis       Date:  2018-08-22       Impact factor: 5.150

2.  Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases.

Authors:  Dipak Panigrahy; Allison Gartung; Jun Yang; Haixia Yang; Molly M Gilligan; Megan L Sulciner; Swati S Bhasin; Diane R Bielenberg; Jaimie Chang; Birgitta A Schmidt; Julia Piwowarski; Anna Fishbein; Dulce Soler-Ferran; Matthew A Sparks; Steven J Staffa; Vidula Sukhatme; Bruce D Hammock; Mark W Kieran; Sui Huang; Manoj Bhasin; Charles N Serhan; Vikas P Sukhatme
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

Review 3.  Chemotherapy-induced metastasis: mechanisms and translational opportunities.

Authors:  George S Karagiannis; John S Condeelis; Maja H Oktay
Journal:  Clin Exp Metastasis       Date:  2018-01-06       Impact factor: 5.150

4.  The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway.

Authors:  Yuxing Zhu; Dong He; Hao Bo; Zexian Liu; Mengqing Xiao; Liang Xiang; Jianda Zhou; Yan Liu; Xiaoming Liu; Lian Gong; Yanni Ma; Yanhong Zhou; Ming Zhou; Wei Xiong; Fei Yang; Xiaowei Xing; Ruhong Li; Wei Li; Ke Cao
Journal:  Oncogene       Date:  2019-07-04       Impact factor: 9.867

5.  Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis.

Authors:  George S Karagiannis; Jessica M Pastoriza; Lucia Borriello; Rojin Jafari; Anouchka Coste; John S Condeelis; Maja H Oktay; David Entenberg
Journal:  J Vis Exp       Date:  2019-06-26       Impact factor: 1.355

Review 6.  Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions.

Authors:  George S Karagiannis; John S Condeelis; Maja H Oktay
Journal:  Cancer Res       Date:  2019-08-20       Impact factor: 12.701

Review 7.  The emerging roles of macrophages in cancer metastasis and response to chemotherapy.

Authors:  Luis Rivera Sanchez; Lucia Borriello; David Entenberg; John S Condeelis; Maja H Oktay; George S Karagiannis
Journal:  J Leukoc Biol       Date:  2019-02-05       Impact factor: 4.962

8.  The ATF3 Transcription Factor Is a Short-Lived Substrate of the Arg/N-Degron Pathway.

Authors:  Tri T M Vu; Alexander Varshavsky
Journal:  Biochemistry       Date:  2020-07-21       Impact factor: 3.162

Review 9.  The pro-tumorigenic host response to cancer therapies.

Authors:  Yuval Shaked
Journal:  Nat Rev Cancer       Date:  2019-10-23       Impact factor: 60.716

10.  Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer.

Authors:  Nawab Azizi; Jelena Toma; Mickenzie Martin; Muhammad Faran Khalid; Fatemeh Mousavi; Phyo Wei Win; Maria Teresa Borrello; Nina Steele; Jiaqi Shi; Marina Pasca di Magliano; Christopher L Pin
Journal:  Oncogene       Date:  2021-04-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.